Frontline therapy of severe aplastic anaemia with fludarabine, cyclophosphamide and ciclosporin
Authors:
Open Access
- 30 March 2015
- journal article
- other
- Published by Wiley in British Journal of Haematology
- Vol. 171 (3) , 427-430
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolutionBlood, 2014
- High-dose cyclophosphamide compared with antithymocyte globulin for treatment of acquired severe aplastic anemiaExperimental Hematology, 2013
- How I treat acquired aplastic anemiaBlood, 2012
- Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic AnemiaNew England Journal of Medicine, 2011
- High-dose cyclophosphamide for severe aplastic anemia: long-term follow-upBlood, 2010
- Survival of patients with documented autologous recovery after SCT for severe aplastic anemia: a study by the WPSAA of the EBMTBone Marrow Transplantation, 2009
- Guidelines for the diagnosis and management of aplastic anaemiaBritish Journal of Haematology, 2009
- Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patientsBlood, 2000
- Prospective Randomized Multicenter Study Comparing Cyclosporin Alone Versus the Combination of Antithymocyte Globulin and Cyclosporin for Treatment of Patients With Nonsevere Aplastic Anemia: A Report From the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working PartyBlood, 1999